IP Library Granted Patent US 11,020,481
Granted Patent B2
US 11,020,481 · App. 15/729,930 · Granted Jun 1, 2021

Topical use of levofloxacin for reducing lung inflammation

Inventors: Michael N. Dudley (San Diego, CA); Ruslan Y. Tsivkovski (San Diego, CA); David C. Griffith (San Marcos, CA); Olga Rodny (Mountain View, CA)
Assignee: Horizon Orphan LLC
A61K45/06A61K31/536A61K31/538A61K31/5383A61K31/7036A61K33/06A61K47/02A61P11/00A61P11/06A61P29/00C07D498/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,020,481
App. No.
15/729,930
Granted
Jun 1, 2021
Kind
B2
Abstract

The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.

Claims (5)

1. A method for treating a pulmonary inflammation in the absence of a pulmonary bacterial infection in a subject in need thereof, the method comprising administering to the subject an aerosol of a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation, a calcium cation, a zinc cation, a copper cation, an aluminum cation, or an iron cation; to treat the pulmonary inflammation; wherein said pulmonary inflammation is an acute or chronic inflammation of a lung.

2. The method of claim 1 , wherein the pulmonary inflammation is an acute or chronic inflammation of an upper airway.

3. The method of claim 1 , wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation.

4. The method of claim 3 , wherein the magnesium cation is in the form of magnesium chloride.

5. The method of claim 1 , wherein the solution has a pH from about 5 to about 8 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg.

Assignments (7)
MERGER AND CHANGE OF NAME Recorded Dec 21, 2023
From: HORIZON THERAPEUTICS, LLC; HORIZON ORPHAN LLC
To: HORIZON THERAPEUTICS U.S. HOLDING LLC
Reel/Frame 065928/0608 →
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA HORIZON ORPHAN LLC)
Reel/Frame 065154/0014 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2021
From: DUDLEY, MICHAEL N; TSIVKOVSKI, RUSLAN Y; GRIFFITH, DAVID C; RODNY, OLGA
To: MPEX PHARMACEUTICALS, INC.
Reel/Frame 056411/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2021
From: MPEX PHARMACEUTICALS, INC.
To: TRIPEX PHARMACEUTICALS, LLC
Reel/Frame 056383/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2021
From: TRIPEX PHARMACEUTICALS, LLC
To: RAPTOR PHARMACEUTICALS INC.
Reel/Frame 056422/0235 →
CHANGE OF NAME Recorded May 28, 2021
From: RAPTOR PHARMACEUTICALS INC.
To: HORIZON ORPHAN LLC
Reel/Frame 056424/0102 →
SECURITY AGREEMENT Recorded May 22, 2019
From: HORIZON ORPHAN LLC
To: CITIBANK, N.A.
Reel/Frame 050253/0855 →